JP2010519235A5 - - Google Patents

Download PDF

Info

Publication number
JP2010519235A5
JP2010519235A5 JP2009550246A JP2009550246A JP2010519235A5 JP 2010519235 A5 JP2010519235 A5 JP 2010519235A5 JP 2009550246 A JP2009550246 A JP 2009550246A JP 2009550246 A JP2009550246 A JP 2009550246A JP 2010519235 A5 JP2010519235 A5 JP 2010519235A5
Authority
JP
Japan
Prior art keywords
riboflavin
mthfr
polymorphism
blood pressure
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009550246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519235A (ja
JP5577100B2 (ja
Filing date
Publication date
Priority claimed from GBGB0703514.0A external-priority patent/GB0703514D0/en
Application filed filed Critical
Publication of JP2010519235A publication Critical patent/JP2010519235A/ja
Publication of JP2010519235A5 publication Critical patent/JP2010519235A5/ja
Application granted granted Critical
Publication of JP5577100B2 publication Critical patent/JP5577100B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009550246A 2007-02-23 2008-02-22 高血圧症治療におけるリボフラビンの使用 Expired - Fee Related JP5577100B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0703514.0A GB0703514D0 (en) 2007-02-23 2007-02-23 Use of riboflavin
GB0703514.0 2007-02-23
PCT/EP2008/001437 WO2008101724A1 (en) 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension

Publications (3)

Publication Number Publication Date
JP2010519235A JP2010519235A (ja) 2010-06-03
JP2010519235A5 true JP2010519235A5 (cg-RX-API-DMAC7.html) 2011-03-31
JP5577100B2 JP5577100B2 (ja) 2014-08-20

Family

ID=37945596

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009550246A Expired - Fee Related JP5577100B2 (ja) 2007-02-23 2008-02-22 高血圧症治療におけるリボフラビンの使用

Country Status (10)

Country Link
US (1) US20100324019A1 (cg-RX-API-DMAC7.html)
EP (1) EP2139488B1 (cg-RX-API-DMAC7.html)
JP (1) JP5577100B2 (cg-RX-API-DMAC7.html)
CN (1) CN101678030B (cg-RX-API-DMAC7.html)
CA (1) CA2679217C (cg-RX-API-DMAC7.html)
EA (1) EA019281B1 (cg-RX-API-DMAC7.html)
ES (1) ES2393144T3 (cg-RX-API-DMAC7.html)
GB (1) GB0703514D0 (cg-RX-API-DMAC7.html)
MX (1) MX2009009020A (cg-RX-API-DMAC7.html)
WO (1) WO2008101724A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358541B (es) * 2012-08-16 2018-08-24 Critical Care Diagnostics Inc Metodos para predecir el riesgo de desarrollar hipertension.
CN103721259A (zh) * 2014-01-07 2014-04-16 深圳奥萨医药有限公司 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物
CN109295216A (zh) * 2018-11-06 2019-02-01 宁波艾捷康宁生物科技有限公司 预测高血压个体化药物药效的snp位点和检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
ATE68704T1 (de) * 1986-12-18 1991-11-15 Bauer Kurt Heinz Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung.
US6485959B1 (en) * 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
CN1136895C (zh) * 2001-05-24 2004-02-04 魏振鸣 一种治疗冠心病的药物
WO2006085128A1 (en) * 2005-02-09 2006-08-17 Wockhardt Limited Cardiovascular therapeutic combinations
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders

Similar Documents

Publication Publication Date Title
FI4076652T3 (fi) Farmaseuttisesti hyväksyttävä atrasentanin suola käytettäväksi iga-nefropatiaan hoitomenetelmässä
Hjermitslev et al. Azilsartan medoxomil, an angiotensin II receptor antagonist for the treatment of hypertension
JP2004514703A (ja) 有機化合物の組合せ剤
CN101384257A (zh) 药物组合
TW200637546A (en) Combination therapy
EP3041463A1 (en) Pulsatile-release dosage form
CN1187050C (zh) 内皮素拮抗剂和血管紧张肽原酶-血管紧张肽系统抑制剂的联合体系
Négrier et al. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management
US7625940B2 (en) Method of treating hypertension with a very low dose of chlorthalidone
AU2006252210B2 (en) New association of a sinus node lf current inhibitor and an angiotensin-converting enzyme inhibitor, and pharmaceutical compositions containing it
EP2446885B1 (en) Therapeutic agent for hypertension or normal high blood pressure
US20190240231A1 (en) Reducing the risk of cardiovascular events
ES2393144T3 (es) Uso de riboflavina en el tratamiento de la hipertensión
Silverstein et al. Angiotensin-receptor blockers: benefits beyond lowering blood pressure
Tamuno et al. Drug treatment for hypertension in a tertiary health care facility in Northern Nigeria
Zannad et al. [PP. 35.03]: SODIUM ZIRCONIUM CYCLOSILICATE FOR TREATMENT OF HYPERKALAEMIA: ANALYSIS OF PATIENTS ON RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS (RAASI) FROM THE PHASE 3 HARMONIZE STUDY
ES2332884T3 (es) Tratamiento de la lipodistrofia con inhibidores del sistema renina angiotensina.
Bernknopf Aliskiren (Tekturna) for the Treatment of Hypertension.
Kaplan Renin‐Angiotensin System Blockade: Therapeutic Implications Beyond Blood Pressure Control
Llorca et al. Interactions between ibuprofen and antihypertensive drugs: Incidence and clinical relevance in dental practice
Chen et al. P-186: Adverse effects and reasons for switch reported by patients on antihypertensive medications
Mohammad et al. Valsartan induced exanthematous macular skin lesions
Carboni et al. Strategies to improve blood pressure control and cardiovascular outcomes in hypertensive patients: medfile
Salinitri et al. Pharmacotherapeutic blood pressure management in a chronic kidney disease patient
Ruilope et al. 24-hour ambulatory blood-pressure effects of valsartan+ hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk